Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Musings from The Power List: Piers Ingram
Piers Ingram discusses the resurgence of immunology, engineering-led drug discovery, and why faster clinical execution will shape the next generation of medicines
Piers Ingram cited the first dual-payload antibody-drug conjugate developed by Hummingbird Bioscience with Callio Therapeutics entering clinical testing as a professional highlight.
2
Ingram said immunology is making underrecognized progress through engineered approaches combining immuno-oncology, antibody-drug conjugates, and T-cell engagers.
3
Ingram identified clinical execution as drug development’s main bottleneck and said better trial execution and use of study data could accelerate innovation.
4
Ingram advocated treating drug discovery as an engineering challenge, using design principles, iterative feedback, and data to improve molecule discovery and optimization.
5
Ingram expects artificial intelligence, computational biology, and advanced laboratory models to reduce reliance on animal models and better reflect human biology.
